Detalhe da pesquisa
1.
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.
Lancet Oncol
; 23(10): 1261-1273, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36108661
2.
A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohort.
Cancer
; 127(17): 3194-3201, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33882143
3.
Emerging drugs for the treatment of adrenocortical carcinoma.
Expert Opin Emerg Drugs
; 26(2): 165-178, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33896321
4.
Multicenter phase 2 trial of nintedanib in advanced nonpancreatic neuroendocrine tumors.
Cancer
; 126(16): 3689-3697, 2020 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32525561
5.
KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid Cancer.
J Natl Compr Canc Netw
; 17(5): 409-413, 2019 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31085763
6.
Prognostic Impact of Serum Pancreastatin Following Chemoembolization for Neuroendocrine Tumors.
Ann Surg Oncol
; 25(12): 3613-3620, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-30182331
7.
Targeting BRAF Mutations in High-Grade Neuroendocrine Carcinoma of the Colon.
J Natl Compr Canc Netw
; 16(9): 1035-1040, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30181415
8.
Management of Cancer Therapeutics-Related Cardiac Dysfunction.
Heart Fail Clin
; 14(4): 553-567, 2018 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-30266364
9.
Safe and successful bone marrow biopsy: an anatomical and CT-based cadaver study.
Am J Hematol
; 89(10): 943-6, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-24942104
10.
Clinical Activity of Selpercatinib in RET-mutant Pheochromocytoma.
J Clin Endocrinol Metab
; 2024 Apr 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38661071
11.
Safety and efficacy of peptide receptor radionuclide therapy in neuroendocrine tumors: A single center experience.
PLoS One
; 19(5): e0298824, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38748739
12.
Selpercatinib for adult patients with locally advanced or metastatic RET-altered solid tumors.
Expert Rev Anticancer Ther
; 23(11): 1117-1122, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37795873
13.
Kinase inhibitors in thyroid cancers.
Endocr Oncol
; 3(1): e220062, 2023 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37434642
14.
Clinical Outcomes of DEB-TACE in Hepatic Metastatic Neuroendocrine Tumors: A 5-Year Single-Institutional Experience.
Acad Radiol
; 30 Suppl 1: S117-S123, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37105803
15.
Neoadjuvant dabrafenib and trametinib for functional organ preservation in recurrent BRAF V600E-mutated papillary thyroid cancer.
Oral Oncol
; 147: 106625, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37948895
16.
Coronary Artery and Peripheral Vascular Disease in a Patient with Poorly Differentiated Thyroid Cancer Treated with the Tyrosine Kinase Inhibitor Lenvatinib.
Case Rep Endocrinol
; 2023: 8841696, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37941892
17.
Health-related quality-of-life analyses from a multicenter, randomized, double-blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day.
Cancer Med
; 12(4): 4332-4342, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36464853
18.
A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms.
Clin Cancer Res
; 29(4): 731-741, 2023 02 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36255391
19.
An Evaluation of Clinical Efficacy of Immune Checkpoint Inhibitors for Patients with Anaplastic Thyroid Carcinoma.
Thyroid
; 32(8): 926-936, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35583228
20.
A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer.
J Clin Endocrinol Metab
; 107(3): 776-787, 2022 02 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34664662